Close Menu

NEW YORK (GenomeWeb News) – Coventry Health Care National Network has terminated its coverage agreement with Sequenom covering the MaterniT21 Plus test, just one week after the agreement was announced, the San Diego-based molecular diagnostics firm said after the close of the market on Thursday.

Coventry told Sequenom that the termination was without cause and was not a judgment on Sequenom, its Sequenom Center for Molecular Medicine subsidiary — which administers the non-invasive test for fetal aneuploidies — or its products, Sequenom said.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A federal judge has ruled that drug companies, device manufacturers, and universities need to provide missing clinical data from hundreds of trials to a federal website, ScienceInsider reports.

NPR reports that the US Centers for Disease Control and Prevention has fixed the problem with some of its SARS-CoV-2 testing kits.

A genetic analysis suggests red pandas might actually belong to two different species, New Scientist reports.

In Nature this week: epigenetic factors that prevent healthy aging and more.

Mar
18
Sponsored by
Roche

This webinar will discuss data from a recent real-world comparison study evaluating performance of two cell-free DNA methodologies as first-line prenatal screens.

Mar
31
Sponsored by
Isoplexis

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.